Adamas Pharmaceuticals Inc (NASDAQ:ADMS) has earned a consensus rating of “Buy” from the fourteen brokerages that are presently covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and twelve have assigned a buy recommendation to the company. The average 12 month price objective among brokerages that have issued ratings on the stock in the last year is $47.71.
ADMS has been the topic of a number of recent analyst reports. HC Wainwright set a $45.00 price target on shares of Adamas Pharmaceuticals and gave the stock a “buy” rating in a research report on Monday, August 6th. BidaskClub lowered shares of Adamas Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Monday, June 18th. ValuEngine lowered shares of Adamas Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, August 28th. Finally, Mizuho reiterated a “buy” rating and issued a $75.00 price objective on shares of Adamas Pharmaceuticals in a research note on Friday, August 17th.
Shares of NASDAQ ADMS traded down $0.17 during midday trading on Thursday, reaching $19.04. The stock had a trading volume of 8,715 shares, compared to its average volume of 472,515. The company has a market capitalization of $541.91 million, a P/E ratio of -4.80 and a beta of 1.37. Adamas Pharmaceuticals has a twelve month low of $17.68 and a twelve month high of $44.00. The company has a debt-to-equity ratio of 0.78, a quick ratio of 9.74 and a current ratio of 9.92.
Adamas Pharmaceuticals (NASDAQ:ADMS) last issued its quarterly earnings results on Thursday, August 2nd. The specialty pharmaceutical company reported ($1.26) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($1.41) by $0.15. The firm had revenue of $7.57 million for the quarter, compared to the consensus estimate of $4.84 million. Adamas Pharmaceuticals had a negative net margin of 1,138.59% and a negative return on equity of 104.86%. analysts forecast that Adamas Pharmaceuticals will post -5.37 earnings per share for the current year.
In other news, CFO Alfred G. Merriweather sold 1,665 shares of Adamas Pharmaceuticals stock in a transaction on Friday, September 21st. The shares were sold at an average price of $19.18, for a total value of $31,934.70. Following the completion of the sale, the chief financial officer now owns 25,460 shares in the company, valued at approximately $488,322.80. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 24.60% of the company’s stock.
A number of hedge funds have recently made changes to their positions in ADMS. BlackRock Inc. increased its stake in Adamas Pharmaceuticals by 24.3% during the 2nd quarter. BlackRock Inc. now owns 1,846,096 shares of the specialty pharmaceutical company’s stock valued at $47,684,000 after purchasing an additional 361,303 shares in the last quarter. Millennium Management LLC increased its stake in Adamas Pharmaceuticals by 318.2% during the 2nd quarter. Millennium Management LLC now owns 342,180 shares of the specialty pharmaceutical company’s stock valued at $8,839,000 after purchasing an additional 260,360 shares in the last quarter. Point72 Asset Management L.P. increased its stake in Adamas Pharmaceuticals by 11.6% during the 2nd quarter. Point72 Asset Management L.P. now owns 2,272,115 shares of the specialty pharmaceutical company’s stock valued at $58,689,000 after purchasing an additional 235,515 shares in the last quarter. UBS Group AG increased its stake in Adamas Pharmaceuticals by 399.4% during the 1st quarter. UBS Group AG now owns 194,503 shares of the specialty pharmaceutical company’s stock valued at $4,649,000 after purchasing an additional 155,559 shares in the last quarter. Finally, Macquarie Group Ltd. increased its stake in Adamas Pharmaceuticals by 12.5% during the 2nd quarter. Macquarie Group Ltd. now owns 1,310,310 shares of the specialty pharmaceutical company’s stock valued at $33,846,000 after purchasing an additional 145,412 shares in the last quarter. Institutional investors and hedge funds own 95.13% of the company’s stock.
About Adamas Pharmaceuticals
Adamas Pharmaceuticals, Inc discovers, develops, and sells therapies for chronic neurologic disorders. The company's approved/commercial product is GOCOVRI, an amantadine therapy for the treatment of levodopa-induced dyskinesia in patients with Parkinson's disease. Its partnered approved/commercial products include Namzaric (memantine hydrochloride extended-release and donepezil hydrochloride) capsules; and Namenda XR (memantine hydrochloride) extended release capsules for the treatment of moderate to severe Alzheimer's disease.
See Also: What is a Fiduciary?
Receive News & Ratings for Adamas Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamas Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.